Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | HK1 | P19367 | 1/20 | 0.65 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.65 |
| ▸ | ATP4A | P20648 | 2/20 | 0.61 |
| ▸ | ATP4B | P51164 | 2/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.58 |
| ▸ | RELA | Q04206 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654020 | 0.92 | CYP19A1 (0.65) | MAPTALDH1A1RAB9AKDM4EMEN1 | |
| SCHEMBL9955024 | 0.84 | CYP19A1 (0.67) | MAPTRAB9AATP4AATP4BCYP19A1 | |
| SCHEMBL3765806 | 0.82 | CYP19A1 (0.60) | MAPTALDH1A1RAB9AHPGDHK1 | |
| SCHEMBL4636395 | 0.81 | TSHR (0.72) | MAPTALDH1A1RAB9AKDM4EMEN1 | |
| SCHEMBL476082 | 0.81 | LTA4H (0.56) | MAPTALDH1A1RAB9AKDM4EMEN1 | |
| SCHEMBL6176532 | 0.81 | CYP19A1 (0.59) | MAPTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL982911 | 0.81 | RECQL (0.66) | MAPTALDH1A1RAB9AKDM4EHPGD | |
| SCHEMBL8362185 | 0.80 | ATP4A (0.59) | MAPTRAB9AATP4AATP4BCYP19A1 | |
| SCHEMBL1399840 | 0.80 | ALDH1A1 (0.76) | MAPTALDH1A1RAB9AKDM4EMEN1 | |
| Iodide SCHEMBL5451467 | 0.79 | LTA4H (0.71) | MAPTALDH1A1RAB9AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092030-A1 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-03-20 | — | — | US | disclosed |
| CN-115466229-B | Para-amidobenzenesulfonyl compound and application thereof | 上海中医药大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-115466229-A | P-acylamino benzenesulfonyl compound and application thereof | 上海中医药大学 | 2022-12-13 | — | — | CN | disclosed |
| CN-115279741-A | 4-phenyl-N- (phenyl) thiazol-2-amine derivatives and related compounds as Aryl Hydrocarbon Receptor (AHR) agonists for the treatment of, for example, angiogenesis-related disorders or inflammatory disorders | 医肯纳肿瘤学公司 | 2022-11-01 | — | — | CN | disclosed |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2022-09-27 | — | — | US | disclosed |
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| CN-107849013-B | Cyanopyrrolidines as DUB inhibitors for the treatment of cancer | 特殊治疗有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-03-10 | — | — | US | disclosed |
| CN-111116575-B | 5-fluoro-2, 4-pyrimidinediamine compound and preparation and application thereof | 浙江工业大学 | 2021-06-15 | — | — | CN | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
| WO-2009118596-A2 | PHTHALIMIDE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118596-A2 | PHTHALIMIDE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2008057862-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-0540143-B1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2003-02-05 | — | — | EP | disclosed |
| US-5714503-A | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 1998-02-03 | — | — | US | disclosed |
| US-5658907-A | THIOUREA VIRICIDES | MEDIVIR A/B (SE) | 1997-08-19 | — | — | US | disclosed |
| US-5593993-A | VIRICIDES FOR HTLV TREATMENT OF AIDS | MEDIVIR AB (SE) | 1997-01-14 | — | — | US | disclosed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | disclosed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | MAPT 1149/4885ALDH1A1 701/4885RAB9A 2258/4885 |
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | DNASE1, RNASEH1, FEN1 | MAPT 1351/4885ALDH1A1 1635/4885RAB9A 2621/4885 |
| US-20250092030-A1 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | PDE2A, GUCY1A1, GCGR | MAPT 4474/4885ALDH1A1 1906/4885RAB9A 960/4885 |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | MAPT 3325/4885ALDH1A1 875/4885RAB9A 1495/4885 |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPC3 | MAPT 1842/4885ALDH1A1 871/4885RAB9A 2497/4885 |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | DNASE1, RNASEH1, FEN1 | MAPT 1351/4885ALDH1A1 1635/4885RAB9A 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.